Cargando…

486 Meropenem and Piperacillin-tazobactam have Comparable Outcomes in Treatment of Bloodstream Infections Caused by Extended Spectrum Beta-lactamase Producing E.coli and Klebsiellae

Detalles Bibliográficos
Autores principales:	Harris, Patrick, Mo, Yin, Jureen, Roland, Chew, Jonathan, Ali, Jaminah, Paterson, David L., Tambyah, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	IDWeek 2014 Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781814/ http://dx.doi.org/10.1093/ofid/ofu052.352

Ejemplares similares

182. Piperacillin/tazobactam (P/T) versus meropenem (Mero) for treatment of extended-spectrum beta-lactamase (ESBL)-producing E.coli and K. pneumoniae bloodstream infections (BSIs)
por: Cox, Alexandra L, et al.
Publicado: (2023)

236 Taking an Antibiotic Timeout: Utilizing an Antibiotic Renewal Template for Automatic Approval of Vancomycin and Piperacillin-tazobactam
por: Graber, Christopher J., et al.
Publicado: (2014)

Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae
por: Harris, Patrick N A, et al.
Publicado: (2015)

760 Piperacillin/Tazobactam-Induced Adverse Drug Events in Pediatric Patients on Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Yusef, Dawood, et al.
Publicado: (2014)

147 An antibiotic stewardship program in the emergency department decreased piperacillin-tazobactam use and increased guideline-concordant antibiotic prescribing for uncomplicated cystitis
por: Haas, Michelle, et al.
Publicado: (2014)

Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin/Tazobactam: Are Extended Infusions to Blame?
por: Navalkele, Bhagyashri, et al.
Publicado: (2015)

479 Clinical outcomes in patients with extended-spectrum-beta-lactamase-producing (ESBL) Enterobacteriaceae bloodstream infections (ESB) treated with carbapenems (CP) and non-carbapenems (NC)
por: Chin, Judy, et al.
Publicado: (2014)

Meropenem/piperacillin/tazobactam: Drug resistance: case report
Publicado: (2021)

257 In Vitro Activity of Meropenem/RPX7009, a Carbapenem/β-lactamase Inhibitor Combination Tested Against Contemporary Populations of Enterobacteriaceae and KPC-producing Strains
por: Castanheira, Mariana, et al.
Publicado: (2014)

402 Pharmacokinetics of Extended vs Intermittent Intravenous Infusion of Meropenem in Critically Ill Patients Receiving Continuous Veno-Venous Haemofiltration
por: Frippiat, Frédéric, et al.
Publicado: (2014)

2746. Assessment of in vitro synergy between Piperacillin-Tazobactam-Meropenem and Imipenem-Meropenem against OXA-48 Producing Klebsiella pneumoniae Using Time-Kill Assays
por: Demir, Mervenur, et al.
Publicado: (2023)

488 Treatment Outcomes in Patients with Extended-Spectrum Beta-lactamase Producing Organisms
por: Lee, Eunbae, et al.
Publicado: (2014)

Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
por: Ng, Tat Ming, et al.
Publicado: (2016)

135 Fosfomycin Susceptibilities Among Uropathogenic Extended Spectrum Beta-Lactamase-producing Enterobacteriacea
por: Abbo, Lilian, et al.
Publicado: (2014)

694 Bone and joint infection due to bacteria producing Extended Broad Spectrum Beta lactamase
por: Rouzaud, Claire, et al.
Publicado: (2014)

194 Antimicrobial Stewardship Evaluation of Meropenem Use at a Large Academic Medical Center
por: Dubrovskaya, Yanina, et al.
Publicado: (2014)

415 In Vitro Potency of Ceftolozane/Tazobactam against Pseudomonas aeruginosa Displaying Multidrug Resistance
por: Sutherland, Christina, et al.
Publicado: (2014)

Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs
por: Barber, Katie E., et al.
Publicado: (2016)

Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial
por: Harris, Patrick NA, et al.
Publicado: (2015)

343 Risk Factors for Extended-Spectrum Beta-Lactamase Infection and Evaluation of Carbapenem Use Patterns and Appropriateness in a County Hospital Setting
por: Su, Henry, et al.
Publicado: (2014)

Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible
por: Baker, Thomas M, et al.
Publicado: (2018)

260 Ceftolozane/Tazobactam for the Treatment of cUTI and cIAI Caused by ESBL-producing Enterobacteriaceae
por: Popejoy, Myra, et al.
Publicado: (2014)

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)
por: Vu, Catherine H., et al.
Publicado: (2022)

1292. Evaluation of Synergy with Piperacillin/Tazobactam plus Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae and Enterobacter cloacae Using ETEST
por: Ashcraft, Deborah S, et al.
Publicado: (2021)

Efficacy and safety of piperacillin–tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing Enterobacteriaceae
por: Zhang, Wei, et al.
Publicado: (2023)

Pragmatic Comparison of Piperacillin/Tazobactam versus Carbapenems in Treating Patients with Nosocomial Pneumonia Caused by Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae
por: Zha, Lei, et al.
Publicado: (2022)

Comparison of Acute Kidney Injury During Treatment with Vancomycin and either Piperacillin-Tazobactam or Meropenem
por: Cannon, John M., et al.
Publicado: (2017)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock()
por: Sun, Yang, et al.
Publicado: (2023)

371 Outcomes of Enterobacter bloodstream infection in hospitalized children
por: Larru, Beatriz, et al.
Publicado: (2014)

251 Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Phase 3 Ceftolozane/Tazobactam Study
por: Miller, Benjamin, et al.
Publicado: (2014)

171 Impact of Rapid Bloodstream Pathogen Identification in Hospitalized Patients
por: Maslonka, Matthew, et al.
Publicado: (2014)

733 Vancomycin-Resistant Enterococcus (VRE) faecium Bloodstream Infections and Mortality
por: Suleyman, Geehan, et al.
Publicado: (2014)

247 Antimicrobial Activity of Ceftolozane/Tazobactam Tested against Gram-negative Bacterial Isolates from Hospitalized Patients with Pneumonia in United States Hospitals (2013)
por: Farrell, David J., et al.
Publicado: (2014)

1285 Evaluation of Manual and Automated Bloodstream Infection Surveillance in Outpatient Dialysis Clinics
por: Thompson, Nicola D., et al.
Publicado: (2014)

715 Impact of Fluoroquinolone Resistance on Community-Onset Gram-Negative Bloodstream Infections
por: Brigmon, Matthew, et al.
Publicado: (2014)

409 Efficacy of Vancomycin against Biofilms of Neonatal Staphylococcus epidermidis Bloodstream Isolates
por: Simitsopoulou, Maria, et al.
Publicado: (2014)

980 Pediatric Patients with Gastrointestinal Conditions and Central Line-Associated Bloodstream Infections
por: Klieger, Sarah B., et al.
Publicado: (2014)

Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model
por: Islam, Kamrul, et al.
Publicado: (2022)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

855 Risk Factors for Peripherally Inserted Central Catheter (PICC) Bloodstream Infection (BSI)
por: Kagan, Evgenia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r49tn5oakirmu69su0i38rr2kg